Inhibrx Biosciences, Inc. (INBX) Institutional Ownership

Ownership Summary

Inhibrx Biosciences, Inc. (NASDAQ:INBX) has 135 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 82.6% of Inhibrx Biosciences's outstanding shares in December 2025, up from 68.0% in September 2025.
• Their total shares held in INBX increased 25.05% from the prior quarter, while the number of investors in Inhibrx Biosciences increased 32.35% year over year.
• Among the 135 funds, 81 bought more Inhibrx Biosciences shares, 38 sold down, and 16 held their ground.
• The aggregate institutional position in Inhibrx Biosciences amounted to 12.79Mn shares as of December 2025, up by 2.56Mn shares quarter on quarter, and up 1.45Mn shares year over year.
• As of December 31, 2025, PERCEPTIVE ADVISORS LLC held the largest stake in Inhibrx Biosciences with 1.45Mn shares, accounting for 9.39% of total shares outstanding.
• The most significant purchases of INBX for the quarter ending December 2025 came from Morgan Stanley (724.87K), Capital Research Global Investors (421.58K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (297.12K), HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND (264.0K), State Street Corp (171.04K).
• Leading sellers of Inhibrx Biosciences shares for the quarter ending December 2025 were VIKING GLOBAL INVESTORS LP (350.0K), Woodline Partners LP (197.11K), KENNEDY CAPITAL MANAGEMENT LLC (90.42K), Groupe la Francaise (31.7K), CITADEL ADVISORS LLC (30.29K).
• Business Quant data shows the 10 biggest positions in Inhibrx Biosciences as of December 2025 are held by PERCEPTIVE ADVISORS LLC (1.45Mn), VIKING GLOBAL INVESTORS LP (1.44Mn), Morgan Stanley (1.17Mn), Sanofi (1.16Mn), HighTower Advisors, LLC (870.51K), BlackRock, Inc. (777.38K), VANGUARD GROUP INC (623.08K), Sofinnova Investments, Inc. (454.66K), Capital Research Global Investors (421.58K), State Street Corp (374.96K).